Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Rose

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
The Oncologist|October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G Najjar, Dustin McCurry, Huang Lin, et al.
Nature Medicine|March 1, 2022
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1John A McCulloch, Diwakar Davar, Richard R Rodrigues, et al.
Science (New York, N.Y.)|February 5, 2021
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patientsDiwakar Davar, Amiran K Dzutsev, John A McCulloch, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 21, 2021
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal modelsAntonella Conforti, Emanuele Marra, Fabio Palombo, et al.
Cancer Cell|November 1, 2024
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trialDiwakar Davar, Robert M Morrison, Amiran K Dzutsev, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
The Oncologist|October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G Najjar, Dustin McCurry, Huang Lin, et al.
Nature Medicine|March 1, 2022
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1John A McCulloch, Diwakar Davar, Richard R Rodrigues, et al.
Science (New York, N.Y.)|February 5, 2021
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patientsDiwakar Davar, Amiran K Dzutsev, John A McCulloch, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 21, 2021
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal modelsAntonella Conforti, Emanuele Marra, Fabio Palombo, et al.
Cancer Cell|November 1, 2024
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trialDiwakar Davar, Robert M Morrison, Amiran K Dzutsev, et al.
Pageof 5